Tweet
Antiviral Res
. 2023 Nov 18:105757.
doi: 10.1016/j.antiviral.2023.105757. Online ahead of print. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization
Qiu-Yan Zhang 1 , Hong-Qing Zhang 2 , Ya-Nan Zhang 1 , Zhe-Rui Zhang 1 , Xiao-Dan Li 3 , Meng-Chan Hao 2 , Yang Zhang 4 , Jia-Qi Li 2 , Yan-Yan Hu 2 , Xiao-Ling Chen 2 , Jing Wang 2 , Yu-Jia Shi 3 , Cheng-Lin Deng 1 , Jian-Jun Chen 2 , Han-Qing Ye 5 , Bo Zhang 6
Affiliations
Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Currently, the development of affordable vaccine against Omicron variant of concern (VOC) is necessary. Here, we assessed the safety and immunogenicity of a SARS-CoV-2 vaccine consisting of a live Newcastle disease virus vector expressing the spike (S) protein of Omicron BA.1 administrated intranasally (IN) or intramuscularly (IM) in Golden Syrian hamster model. Immunogenicity studies showed that the prime-boost regimen elicited high antibody titers and the modified S antigen (Sm-F) could induce robust antibody response in low dosage immunization through IN route. Sera of the immunized hamsters provided effective cross-neutralizing activity against different Omicron variants, the prototype and delta strains of SARS-CoV-2. Moreover, the vaccine could provide complete immunoprotection in hamsters against the Omicron BA.1 challenge by either intranasal or intramuscular immunization. Overall, our study provides an alternative nasal vaccine against the SARS-CoV-2 Omicron variants.
Keywords: Intranasal immunization; NDV vector vaccine; Omicron variant.
. 2023 Nov 18:105757.
doi: 10.1016/j.antiviral.2023.105757. Online ahead of print. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization
Qiu-Yan Zhang 1 , Hong-Qing Zhang 2 , Ya-Nan Zhang 1 , Zhe-Rui Zhang 1 , Xiao-Dan Li 3 , Meng-Chan Hao 2 , Yang Zhang 4 , Jia-Qi Li 2 , Yan-Yan Hu 2 , Xiao-Ling Chen 2 , Jing Wang 2 , Yu-Jia Shi 3 , Cheng-Lin Deng 1 , Jian-Jun Chen 2 , Han-Qing Ye 5 , Bo Zhang 6
Affiliations
- PMID: 37984567
- DOI: 10.1016/j.antiviral.2023.105757
Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Currently, the development of affordable vaccine against Omicron variant of concern (VOC) is necessary. Here, we assessed the safety and immunogenicity of a SARS-CoV-2 vaccine consisting of a live Newcastle disease virus vector expressing the spike (S) protein of Omicron BA.1 administrated intranasally (IN) or intramuscularly (IM) in Golden Syrian hamster model. Immunogenicity studies showed that the prime-boost regimen elicited high antibody titers and the modified S antigen (Sm-F) could induce robust antibody response in low dosage immunization through IN route. Sera of the immunized hamsters provided effective cross-neutralizing activity against different Omicron variants, the prototype and delta strains of SARS-CoV-2. Moreover, the vaccine could provide complete immunoprotection in hamsters against the Omicron BA.1 challenge by either intranasal or intramuscular immunization. Overall, our study provides an alternative nasal vaccine against the SARS-CoV-2 Omicron variants.
Keywords: Intranasal immunization; NDV vector vaccine; Omicron variant.